Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement the presentation of BETonMACE results to be made during the American Heart Association's ("AHA") annual conference. As previously reported, the primary results of the BETonMACE trial will be presented on November 16 during the AHA's Scientific Sessions 2019 held in Philadelphia, Pennsylvania; additional details can be found HERE. Following the AHA presentation, the Company will host a conference call and webcast currently scheduled for 8:30 am ET on November 18, 2019.

Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. A total of 66,053,596 shares (approximately 31.54% of outstanding common shares) were represented in person or by proxy.

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announces that it has issued a 10% secured convertible debenture in the principal amount of US$12 million (the "Debenture") to a wholly-owned subsidiary of ORI Star Fund LP ("ORI" or the "Fund"). The Debenture bears interest at a rate of 10% per annum and matures on September 26, 2020. The Fund may elect to convert the Debenture into common shares of the Company at a conversion price equal to the lesser of CAD$2.54 per share and the 5-day volume weighted average trading price of the common shares on the date of conversion. The Company granted the Fund a security interest in all of its assets, including its patents and other intellectual property, as security for its obligations under the Debenture. In addition, the Fund received 600,000 common share purchase warrants exercisable until December 31, 2023 at a price of CAD$2.54 per share.